Biopharma-mea Information

Biopharma-mea is a regional specialty biopharmaceutical partner dedicated to expanding access to innovative, rare, genetic, and specialty therapies across the GCC and Egypt, with ongoing expansion across the wider MENA region. Founded in 2007, Biopharma-mea was built to bridge the gap between global innovation and patients with high unmet medical needs. Today, we collaborate with leading international biotech and pharmaceutical innovators, ranging from emerging biotech to established global companies, to bring transformative therapies closer to patients across the region. Our model goes beyond traditional distribution. We operate as a demand creation and market development partner, supporting our principals across the full value chain — including regulatory strategy, market access, medical engagement, and commercial execution. Our global partners include leading innovators such as BioMarin, Vertex, Denali, Orchard Therapeutics, Juvise, Gilead, LG Chem, Pfizer, ImmunityBio, and LEO Pharma, spanning a diversified portfolio across: Rare & Genetic Diseases, Gene Therapy, Oncology, Hematology, Immunology, Infectious Diseases, Endocrinology, and Infertility. At Biopharma-mea, we are guided by our core values & remaining committed to improving patient outcomes through science, collaboration, and sustainable access.